Differential interactions of phenobarbital and pentobarbital with beta-adrenergic mechanisms in vitro and in vivo.
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001001:Anura; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D051379:Mice; D010424:Pentobarbital / Q000494:pharmacology*; D010634:Phenobarbital / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011894:Rana pipiens; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D012584:Sciatic Nerve / Q000187:drug effects; D012640:Seizures / Q000188:drug therapy; D013015:Sotalol / Q000494:pharmacology
D011941:Receptors, Adrenergic; D011943:Receptors, Adrenergic, beta; D003994:Bucladesine; D011433:Propranolol; D013015:Sotalol; D000242:Cyclic AMP; D010424:Pentobarbital; D007545:Isoproterenol; D002118:Calcium; D004837:Epinephrine; D010634:Phenobarbital; D010646:Phentolamine